Clinical Trial

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2025 (before its estimated December 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators hypothesize that the addition of bevacizumab and pembrolizumab to induction cisplatin and gemcitabine is tolerable and improves metabolic complete response (mCR), relapse free survival (RFS) and overall survival (OS) compared to induction cisplatin and gemcitabine in patients with locally advanced nasopharyngeal cancer (NPC)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-03-22.
Status change: Not Yet Recruiting → Recruiting 2025-09-21
Trial Details
NCT Number NCT05305131
Lead Sponsor National University Hospital, Singapore
Conditions Nasopharyngeal Cancer
Enrollment 50 participants
Start Date 2022-03-28
Primary Completion 2025-12-28 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2025-09-23